Everyone who needs a transplant deserves an optimal match.
At Pirche, we revolutionize transplant medicine and immunotherapy through cutting-edge technology and unparalleled precision.
Why choose pirche
Precision
Epitope-level matching provides a finer degree of compatibility assessment over traditional HLA matching.
Reliability
Backed by extensive research in over 250,000 cases and >80 publications on clinical validation, PIRCHE has been validated across all solid-organ types and bone marrow transplantation.
Innovation
Our dedication to continual refinement of algorithms ensures our technology stays at the forefront of transplantation science and the clinician and the transplant patient receive world-class HLA risk assessments
Our partners
Transplant Medicine
Compatibility between a recipient and a donor is at the core of success in solid-organ and bone marrow transplantation.
PIRCHE focuses on predicting how well the recipient's immune system will recognize and respond to the donor organ based on HLA epitopes.
Minimize Graft versus Host Disease
Guiding immunosuppressive therapy
Optimizing biomarker monitoring
Donor selection
Technology
TxPredictor
Our state-of-the-art platform, TxPredictor, merges genetic typing with real-time, AI-supported immunological simulations, enabling clinicians to make precise, personalized medical decisions.
The Pirche TxPredictor platform uses T and B cell epitope predictors, allowing clinicians and laboratories to interact with their patient’s tissue compatibility data like never before. Running on a high-performance cloud infrastructure, it combines real time analysis with clear user interfaces.
By leveraging standard clinical lab results and seamlessly integrating with leading laboratory IT systems, we provide a plug-and-play solution that transforms patient care.
Highlights & features
Absolute and relative immunologic risk quantification
Low resolution HLA typing support
Real time & cloud based
Low turnaround time
Integration with major HLA vendors’ software
No maintenance
Cell Therapy
PIRCHE epitope matching reduces the risk of immune rejection, by identifying donors whose cells are less likely to be recognised as foreign. This is crucial in allogeneic cell therapy where mismatched donor cells can lead to immune-mediated destruction of the therapeutic cells.
Pirche can help
Identify optimal
‘off-the-shelf’ therapy
Minimize Graft versus Host Disease
Optimize therapy efficacy and safety
